Fri, Jul 25, 2014, 11:32 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Neuralstem, Inc. Message Board

  • stahlz2000 stahlz2000 Jun 29, 2013 3:49 AM Flag


    As I have stated , too much good news is a problem if certain players are trying to hold the share price down .
    You have to be deaf , dumb and blind not to understand there are a lot of true investors jumping onboard .
    The FDA likes what they see .
    Big pharma will surely want to partner up with Neuralstem
    The questions will be Who , When and naturally the KEY FACTORS in the deal
    Neuralstem has a lot to offer.
    It would be terrific as a shareholder if we saw a bidding war .
    Perfect timing !

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Its about time. Im long on this stock and not budging and apparently a lot of others aren't too. The volume has been quite low but the price held it because the longs are just not selling?
      The CEO is not real happy with big Pharma or the FDA. He took some pretty good shots at both of them in his presentation at the Annual World Stem Cells And Regenerative Medicine Congress In London.
      IMO.. I think NSI-566 will be fast tracked so if someone wants to bid for CUR they better do it now

      • 2 Replies to yukpup88
      • Yukpup88, you should definitely check out the youtube video, which Alex is referring to. It was very good presentation.

        "FIGHTING ALS" by CNN will cover for next three days. In the midst, Dr. Sanjay Gupta will likely follow up with CNN previously covered article on CUR FDA-Approved clitical trial by Miriam Falco.

        Also, there is a rumor that another Korean firm/corp is currently interest in investing on CUR besides the CJ Group.

        Right now, CVS pharmacy started awarness on ALS, too.

        Sentiment: Strong Buy

      • Regarding CEO Garr's comments (to which you referred) - everyone should see the excellent presentation by Garr at that event in late May. You can find it on youtube, the title is "Neuralstem CEO Richard Garr Presents at World Stem Cells Regenerative Medicine Congress 2013". It includes some very eye-opening graphs of ALS patient stability when treated with NSI-566.

        Sentiment: Strong Buy

    • I personally own some AZN and I would love to see an AZN bid. We need to build our business and CUR can offer some great competition to SNY, MRK and GSK. I know AZN management prefers to buy success rather than endure the great risks associated with the original research. CUR presents well so I guess I will just hope for an AZN bid.

      • 1 Reply to coachzack
      • Neuralstem should be important enough to see a bidding war between a couple of the big pharmas .
        Stem Cells is where it's at for the foreseeable future .
        CUR will be the CURingest stock for many tough diseases..
        The world including the FDA certainly knows how tough ALS has been to find a cure and Neuralstem is constantly making dents in it's armor thanks to Eva Feldman and the CUR crew .

3.20-0.05(-1.54%)Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.